Nautilus Bio (NAUT) Stock Forecast, Price Target & Predictions
NAUT Stock Forecast
Nautilus Bio stock forecast is as follows: an average price target of $6.00 (represents a 156.41% upside from NAUT’s last price of $2.34) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
NAUT Price Target
The average price target for Nautilus Bio (NAUT) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 156.41% upside from NAUT's last price of $2.34.
NAUT Analyst Ratings
According to 3 Wall Street analysts, Nautilus Bio's rating consensus is 'Buy'. The analyst rating breakdown for NAUT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 1 'Hold' (33.33%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Nautilus Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 27, 2024 | Subbu Nambi | Guggenheim | $6.00 | $2.29 | 162.58% | 156.41% |
The latest Nautilus Bio stock forecast, released on Jun 27, 2024 by Subbu Nambi from Guggenheim, set a price target of $6.00, which represents a 162.58% increase from the stock price at the time of the forecast ($2.29), and a 156.41% increase from NAUT last price ($2.34).
Nautilus Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $6.00 |
| Last Closing Price | $2.34 | $2.34 | $2.34 |
| Upside/Downside | -100.00% | -100.00% | 156.41% |
In the current month, the average price target of Nautilus Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nautilus Bio's last price of $2.34. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 27, 2024 | Guggenheim | - | Buy | Initialise |
| Jun 03, 2024 | Jefferies | - | Hold | Downgrade |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
Nautilus Bio's last stock rating was published by Guggenheim on Jun 27, 2024. The company Initialise its NAUT rating from "null" to "Buy".
Nautilus Bio Financial Forecast
Nautilus Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $2.57M | $968.75K | $156.25K | $325.00K | $153.25K | $1.83M | $391.67K | $177.00K | $166.67K |
| High Forecast | $2.57M | $968.75K | $156.25K | $325.00K | $154.88K | $1.83M | $391.67K | $177.00K | $166.67K |
| Low Forecast | $2.57M | $968.75K | $156.25K | $325.00K | $151.63K | $1.83M | $391.67K | $177.00K | $166.67K |
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - |
Nautilus Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NAUT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nautilus Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-15.22M |
| Avg Forecast | - | - | - | - | - | - | - | - | $-18.07M |
| High Forecast | - | - | - | - | - | - | - | - | $-14.46M |
| Low Forecast | - | - | - | - | - | - | - | - | $-21.68M |
| Surprise % | - | - | - | - | - | - | - | - | 0.84% |
undefined analysts predict NAUT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nautilus Bio's previous annual EBITDA (undefined) of $NaN.
Nautilus Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-15.50M |
| Avg Forecast | $-24.78M | $-24.09M | $-23.08M | $-22.08M | $-20.32M | $-20.70M | $-20.57M | $-20.39M | $-18.72M |
| High Forecast | $-24.78M | $-24.09M | $-23.08M | $-18.40M | $-19.05M | $-20.70M | $-20.57M | $-20.39M | $-14.97M |
| Low Forecast | $-24.78M | $-24.09M | $-23.08M | $-24.53M | $-20.32M | $-20.70M | $-20.57M | $-20.39M | $-22.46M |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% |
Nautilus Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NAUT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nautilus Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $6.36M |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
Nautilus Bio's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to NAUT last annual SG&A of $6.36M (Mar 22).
Nautilus Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.12 |
| Avg Forecast | $-0.20 | $-0.19 | $-0.18 | $-0.18 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $-0.16 |
| High Forecast | $-0.20 | $-0.19 | $-0.18 | $-0.15 | $-0.15 | $-0.17 | $-0.16 | $-0.16 | $-0.16 |
| Low Forecast | $-0.20 | $-0.19 | $-0.18 | $-0.20 | $-0.16 | $-0.17 | $-0.16 | $-0.16 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | 0.76% |
According to undefined Wall Street analysts, Nautilus Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NAUT previous annual EPS of $NaN (undefined).
Nautilus Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.26 | $15.00 | 1090.48% | Buy |
| PMVP | PMV Pharmaceuticals | $1.57 | $18.00 | 1046.50% | Buy |
| MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| BCAB | BioAtla | $1.48 | $5.00 | 237.84% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $13.50 | 233.33% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
| NAUT | Nautilus Bio | $2.34 | $6.00 | 156.41% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| BEAM | Beam Therapeutics | $24.49 | $58.50 | 138.87% | Buy |
| DTIL | Precision BioSciences | $7.18 | $15.50 | 115.88% | Buy |
| FHTX | Foghorn Therapeutics | $7.86 | $16.33 | 107.76% | Buy |
| CRBU | Caribou Biosciences | $1.96 | $3.00 | 53.06% | Buy |
| KYMR | Kymera Therapeutics | $44.05 | $51.50 | 16.91% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $57.07 | $60.63 | 6.24% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |